Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 333-336

  Pankuch, Glenn A ^a   Lin, Gengrong ^a   Seifert, Harald ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COLISTIN; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 37849040424     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00689-07     Document Type: Article

References (27)

1. Bajaksouzian, S., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1996. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob. Agents Chemother. 40:1973-1976.
2. Bajaksouzian, S., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1997. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters determined by checkerboard and time-kill studies. Antimicrob. Agents Chemother. 41:1073-1076.
3. Cappelletty, D. M., and M. R. Rybak. 1996. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:677-683.
4. Carlet, J., A. Ben Ali, and A. Chalfine. 2004. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr. Opin. Infect. Dis. 17:309-316.
5. Clark, C. L., M. R. Jacobs, and P. C. Appelbaum. 1999. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high. Antimicrob. Agents Chemother. 43:2295-2298.
6. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, seventh edition. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Credito, K., G. Lin, and P. C. Appelbaum. 2007. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus by time-kill methodology. Antimicrob. Agents Chemother. 51:1504-1507.
8. Eliopoulos, G. M., and R. C. Moellering, Jr. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, MD.
9. Falagas, M. E., P. K. Koletski, and I. A. Bliziotis. 2006. The diversity of definitions of multi-drug resistant (MDR) and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 55:1619-1629.
10. Fisher, R. A. 1990. Statistical methods, experimental design and scientific inference. Oxford University Press, Inc., New York, NY.
11. Fraenkel, C. J., M. Ullberg, S. Bernander, E. Ericson, P. Larsson, J. Rydberg, E. Tornqvist, and A. Melhus. 2006. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals. Scand. J. Infect. Dis. 38:853-859.
12. Giamarellou, H. 2006. Treatment options for multidrug-resistant bacteria. Expert Rev. Anti-Infect. Ther. 4:601-618.
13. Goossens, H. 2003. Susceptibility of multi-drug resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin. Microbiol. Infect. 9:980-983.
14. Greenhalgh, J. M., and J. R. Edwards. 1997. A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics. Clin. Microbiol. Infect. 3(Suppl. 4):S20-S31.
15. Grundmann, H. J., K. J. Towner, L. Dijkshoorn, P. Gerner-Smidt, M. Maher, H. Seifert, and M. Vaneechoutte. 1997. Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp. J. Clin. Microbiol. 35:3071-3077.
16. Hawley, J. S., C. K. Murray, M. E. Griffith, M. L. McElmeel, L. C. Fulcher, D. R. Hospenthal, and J. H. Jorgensen. 2007. Susceptibility of Acinetobacter strains isolated from deployed U.S. martial personnel. Antimicrob. Agents Chemother. 51:376-378.
17. Héritier, C., A. Dubouix, L. Poirel, N. Marty, and P. Nordmann. 2005. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J. Antimicrob. Chemother. 55:115-118.
18. Hujer, K. M., A. M. Hujer, E. A. Hulten, S. Bajaksouzian, J. M. Adams, C. J. Donskey, D. J. Ecker, C. Massire, M. W. Eshoo, R. Sampath, J. M. Thompson, P. N. Rather, D. W. Craft, J. T. Fishbain, A. J. Ewell, M. R. Jacobs, D. L. Paterson, and R. A. Bonomo. 2006. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 50:4114-4123.
19. Jones, R. N., R. N. Kehrberg, M. E. Erwin, and S. C. Anderson. 1994. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistance: real or perceived? Fluoroquinolone resistance surveillance group. Diagn. Microbiol. Infect. Dis. 19:203-215.
20. Kiska, D. L., and P. H. Gilligan. 2003. Pseudomonas, p. 719-728. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed., vol. 1. ASM Press, Washington, D.C.
21. Solak, S., A. Willke, O. Ergonül, and E. Tekeli. 2005. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 25:181-182.
22. Unal, S., and J. A. Garcia-Rodriguez. 2005. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. Isolated in the MYSTIC Program, 2002-2004. Diagn. Microbiol. Infect. Dis. 53:265-271.
23. Valenzuela, J. K., L. Thomas, S. R. Partridge, T. van der Reijden, L. Dijkshoorn, and J. Iredell. 2007. Horizontal gene transfer within a polyclonal outbreak of carbapenem-resistant Acinetobacter baumannii. J. Clin. Microbiol. 45:453-460.
24. Vaneechoutte, M., L. Dijkshoorn, I. Tjernberg, A. Elaichouni, P. de Vos, G. Claeys, and G. Verschraegen. 1995. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J. Clin. Microbiol. 33:11-15.
25. Visalli, M. A., S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 1997. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1475-1481.
26. Visalli, M. A., M. R. Jacons, and P. C. Appelbaum. 1998. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob. Agents Chemother. 42:953-955.
27. Visalli, M. A., M. R. Jacons, and P. C. Appelbaum. 1998. Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 42:2002-2005.